Fundraising FoxAI-powered Drug Discovery Startups
37 companies tagged AI-powered Drug Discovery, with their investors and founders.
Parallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.
10 investors
Qvin develops the Q-Pad, an FDA-cleared diagnostic menstrual pad that collects menstrual blood samples for non-invasive health monitoring and disease diagnosis. The company uses biomarker analysis from menstrual fluid to serve healthcare organizations and diagnostic platforms in women's health diagnostics.
9 investors
1910 develops an AI platform that integrates multimodal data, frontier AI models, and high-throughput lab automation to accelerate drug discovery and development for pharmaceutical companies. The platform targets undruggable targets and aims to improve R&D productivity in the biopharma industry.
8 investors
Adaptyv Bio develops technologies for protein engineering that enable the design and testing of new proteins for applications in medicine, industrial enzymes, and functional materials. The company serves protein engineers and researchers developing therapeutic and industrial biological products.
8 investors
Ångström AI develops AI-powered physics simulations for pharmaceutical drug discovery, computing molecular properties like solubility, lipophilicity, and crystal structure stability to replace traditional lab experiments. The platform uses machine learning interatomic potentials and free energy calculations to accelerate and derisk solid form development for pharma companies.
8 investors
Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.
8 investors
Shiru uses AI and material science to discover natural proteins and ingredients for use in food, personal care, agriculture, and advanced materials, reducing traditional development timelines from 5-15 years to 1-2 years.
8 investors
Menten AI develops generative AI software to design cyclic peptide therapeutics for drug targets beyond the reach of conventional small molecules and biologics. The company partners with major pharmaceutical firms to accelerate preclinical drug discovery.
7 investors
Numerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.
7 investors
Persephone develops a synbiotic supplement for infants that combines probiotics (keystone Bifidobacterium strains) with prebiotics found in human breast milk to replenish gut bacteria linked to digestion, immunity, and development. The product was developed by microbiome scientists and pediatricians and validated in a clinical study.
7 investors
Reverie Labs develops cancer treatments designed to cross the blood-brain barrier and treat tumors in the central nervous system.
7 investors
Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.
6 investors
SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
6 investors
Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.
5 investors
Output builds generative AI models trained on biological data to discover and develop medicines. The company focuses on applying large biological models to improve diagnosis, treatment, and disease prevention.
5 investors
Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules. The platform integrates state-of-the-art published tools like AlphaFold and RFdiffusion through a user-friendly interface for life sciences companies.
5 investors
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
4 investors
CellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research. The company serves biopharmaceutical companies and therapy developers seeking to understand cellular function and phenotype.
4 investors
Diffuse designs proteins using AI models trained on experimental data collected through proprietary assays and software, delivering validated AI-designed proteins to partners.
4 investors
Harmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.
4 investors
Known Medicine develops a predictive engine using AI and patient datasets to identify optimal cancer treatments for individual patients. The company serves oncologists and cancer patients through computational analysis of biomaterials and drug-discovery data.
4 investors
b12 develops AI agents and lab automation software to help chemists plan, optimize, and execute the synthesis of complex molecules. The platform combines chemistry expertise with agentic AI systems to streamline organic synthesis workflows.
3 investors
Lavo Life Sciences offers computational molecular simulations to pharmaceutical companies, helping them optimize drug formulations, reduce experimental costs, and accelerate the path to clinical trials and regulatory approval.
3 investors
Matrubials develops antimicrobial peptides derived from milk to create novel therapeutics for bacterial infections, starting with bacterial vaginosis. The company uses AI-enabled technology to identify and validate bioactive molecules for infectious disease treatments.
3 investors